| Target Molecule | Glucagon (1-29) |
| Synonyms | Glucagon (1-29) (human), GCG, pancreatic glucagon, HG-1 |
| CAS Number | 16941-32-5 (free base); 11140-85-5 (hydrochloride salt) |
| Sequence (3-Letter) | H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH |
| Sequence (1-Letter) | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT |
| Molecular Formula | C₁₅₃H₂₂₅N₄₃O₄₉S (free base) |
| Molecular Weight | 3482.75 (free base); hydrochloride salt ≈ 3519.2 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Free base / TFA (hydrochloride salt and custom options available) |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) for Linear Unmodified Sequences |
| Modification Options | Oxidation control, stable isotope labeling (13C, 15N), structural analogues, oxidized variant impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, and MS identity confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Glucagon (CAS 16941-32-5) is a conserved 29-residue linear peptide hormone serving as the native structural template for metabolic receptor agonists. We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for metabolic research and impurity profiling.
The sequence contains oxidation-prone residues, notably a reactive tryptophan (Trp25) and methionine (Met27). Our peptide synthesis platform utilizes optimized solid-phase peptide synthesis (SPPS) protocols, specific cleavage scavengers, and inert gas handling to suppress oxidation and truncation during synthesis.
Free-base Glucagon is poorly soluble in neutral water and prone to amyloid-like fibril aggregation, complicating purification. Our peptide modification services navigate these constraints through pH-optimized handling procedures, while providing specific oxidized variants as stability-indicating standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize pH-controlled preparative HPLC purification and controlled counter-ion exchange (providing the free base or converting to the hydrochloride salt) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, aggregation suppression, impurity profiling, analytical method validation, and regulatory documentation to advance complex therapeutic pipelines.
Glucagon (CAS 16941-32-5) is the native 29-amino-acid peptide hormone responsible for counter-regulating insulin. Defined by the sequence HSQGTFTSDYSKYLDSRRAQDFVQWLMNT, it serves as an essential structural benchmark for metabolic receptor research. Synpeptide provides comprehensive custom synthesis solutions for this molecule, showcasing our technical capabilities in linear chain assembly, oxidation control, and CDMO manufacturing.
Constructing a 29-amino acid sequence requires strict control over each synthetic cycle to prevent sequence deletions. The presence of methionine (Met27) and tryptophan (Trp25) renders the peptide susceptible to oxidation and degradation during cleavage. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins, specific cleavage scavengers, and inert gas handling to deliver raw materials with rigorous purity specifications (typically ≥98% via HPLC).
A primary challenge in Glucagon manufacturing is its pronounced tendency to form beta-sheet fibrils and aggregate in neutral aqueous solutions. Through our peptide modification services, we navigate these solubility constraints by optimizing pH-dependent handling procedures. Furthermore, we synthesize specific oxidized variants and structural analogues to serve as vital reference standards for stability-indicating analytical assays.
Transitioning a 29-residue, aggregation-prone peptide from analytical scale to commercial volume demands robust downstream processing. We execute large-scale peptide synthesis for Glucagon by utilizing pH-controlled gradient HPLC purification to prevent fibrillization. We offer precise counter-ion control, supplying the peptide as either the poorly soluble free base or converting it to the widely utilized hydrochloride salt across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream clinical-stage programs.
